Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI3506 (Tozorakimab) PK/PD in Healthy Chinese Participants
NCT05070312Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tozorakimab in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis (AD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed concentration, Area under the serum concentration time curve to the infinite and 5 more. Started Aug 2021; status: completed.
02
Drugs
tozorakimab
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05070312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070312.